Cache Advisors LLC Takes $455,000 Position in Johnson & Johnson (NYSE:JNJ)

Cache Advisors LLC purchased a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,145 shares of the company's stock, valued at approximately $455,000.

Other hedge funds also recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new stake in Johnson & Johnson during the 4th quarter worth about $8,728,000. University of Texas Texas AM Investment Management Co. grew its holdings in Johnson & Johnson by 3.5% during the fourth quarter. University of Texas Texas AM Investment Management Co. now owns 9,684 shares of the company's stock worth $1,400,000 after buying an additional 323 shares in the last quarter. Parr Mcknight Wealth Management Group LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $7,991,000. Neo Ivy Capital Management lifted its position in shares of Johnson & Johnson by 3,733.5% during the 4th quarter. Neo Ivy Capital Management now owns 57,042 shares of the company's stock worth $8,249,000 after buying an additional 55,554 shares in the last quarter. Finally, Vega Investment Solutions bought a new stake in Johnson & Johnson during the fourth quarter worth $83,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ traded down $0.61 during mid-day trading on Wednesday, reaching $152.64. 2,422,983 shares of the company were exchanged, compared to its average volume of 9,321,002. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company's 50 day moving average price is $154.85 and its 200 day moving average price is $153.65. The stock has a market capitalization of $367.26 billion, a PE ratio of 22.95, a PEG ratio of 2.56 and a beta of 0.42. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.41%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Morgan Stanley increased their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 16th. Raymond James reduced their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Barclays dropped their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Finally, Bank of America lowered their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Eleven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.